JP2020055849A5 - - Google Patents

Download PDF

Info

Publication number
JP2020055849A5
JP2020055849A5 JP2019220807A JP2019220807A JP2020055849A5 JP 2020055849 A5 JP2020055849 A5 JP 2020055849A5 JP 2019220807 A JP2019220807 A JP 2019220807A JP 2019220807 A JP2019220807 A JP 2019220807A JP 2020055849 A5 JP2020055849 A5 JP 2020055849A5
Authority
JP
Japan
Prior art keywords
tau
binding
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019220807A
Other languages
English (en)
Japanese (ja)
Other versions
JP7100008B2 (ja
JP2020055849A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020055849A publication Critical patent/JP2020055849A/ja
Publication of JP2020055849A5 publication Critical patent/JP2020055849A5/ja
Priority to JP2022105415A priority Critical patent/JP7413448B2/ja
Application granted granted Critical
Publication of JP7100008B2 publication Critical patent/JP7100008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019220807A 2015-07-06 2019-12-06 Ｔａｕ結合抗体 Active JP7100008B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022105415A JP7413448B2 (ja) 2015-07-06 2022-06-30 Ｔａｕ結合抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15175522 2015-07-06
EP15175522.0 2015-07-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018500423A Division JP6630426B2 (ja) 2015-07-06 2016-07-05 Ｔａｕ結合抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105415A Division JP7413448B2 (ja) 2015-07-06 2022-06-30 Ｔａｕ結合抗体

Publications (3)

Publication Number Publication Date
JP2020055849A JP2020055849A (ja) 2020-04-09
JP2020055849A5 true JP2020055849A5 (enExample) 2020-07-02
JP7100008B2 JP7100008B2 (ja) 2022-07-12

Family

ID=53524640

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018500423A Active JP6630426B2 (ja) 2015-07-06 2016-07-05 Ｔａｕ結合抗体
JP2019220807A Active JP7100008B2 (ja) 2015-07-06 2019-12-06 Ｔａｕ結合抗体
JP2022105415A Active JP7413448B2 (ja) 2015-07-06 2022-06-30 Ｔａｕ結合抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018500423A Active JP6630426B2 (ja) 2015-07-06 2016-07-05 Ｔａｕ結合抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022105415A Active JP7413448B2 (ja) 2015-07-06 2022-06-30 Ｔａｕ結合抗体

Country Status (31)

Country Link
US (4) US10287343B2 (enExample)
EP (2) EP4729538A3 (enExample)
JP (3) JP6630426B2 (enExample)
KR (2) KR20250027278A (enExample)
CN (1) CN107849104B (enExample)
AR (1) AR105267A1 (enExample)
AU (1) AU2016289755C1 (enExample)
CA (1) CA2991451A1 (enExample)
CL (1) CL2018000043A1 (enExample)
CO (1) CO2017012971A2 (enExample)
EA (1) EA037092B1 (enExample)
EC (1) ECSP18000887A (enExample)
ES (1) ES3060419T3 (enExample)
HR (1) HRP20260348T1 (enExample)
IL (1) IL256685B (enExample)
MA (2) MA42377B1 (enExample)
MD (1) MD3319983T2 (enExample)
MX (1) MX2017015817A (enExample)
MY (1) MY193677A (enExample)
PE (1) PE20180481A1 (enExample)
PH (1) PH12017502207B1 (enExample)
PL (1) PL3319983T3 (enExample)
RS (1) RS67937B1 (enExample)
SG (1) SG10202010735PA (enExample)
SM (1) SMT202600068T1 (enExample)
TN (1) TN2017000539A1 (enExample)
TW (1) TWI745295B (enExample)
UA (1) UA124616C2 (enExample)
UY (1) UY36773A (enExample)
WO (1) WO2017005734A1 (enExample)
ZA (1) ZA201800027B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
EP3551655A2 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
EP3551220B1 (en) 2016-12-07 2025-01-29 Genentech, Inc. Anti-tau antibodies and methods of use
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
US20220299527A1 (en) * 2019-08-13 2022-09-22 Washington University Methods to detect mtbr tau isoforms and use thereof
CA3167317C (en) 2020-02-12 2025-05-27 Eli Lilly And Company CRYSTALLIZATION OF ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS
CN116723856A (zh) 2020-06-25 2023-09-08 默沙东有限责任公司 靶向丝氨酸413处磷酸化的tau的高亲和力抗体
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
CR20250208A (es) * 2022-11-14 2025-08-04 Washington University St Louis Métodos para detectar mtbr-tau en lcr y usos de los mismos
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025171285A1 (en) * 2024-02-09 2025-08-14 University Of Notre Dame Du Lac Tau proteomimetics
WO2025196217A1 (en) 2024-03-21 2025-09-25 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies
WO2026057816A1 (en) 2024-09-13 2026-03-19 UCB Biopharma SRL Treatment of tauopathies with tau-binding antibodies
WO2026093448A1 (en) * 2024-10-30 2026-05-07 Universiteit Utrecht Holding B.V. Single-domain antibodies targeting the heparin-binding egf-like growth factor
WO2026102093A1 (en) 2024-11-07 2026-05-15 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2745527A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Leptin and leptin analog conjugates and uses thereof
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
WO2011041897A1 (en) 2009-10-06 2011-04-14 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3275461A1 (en) 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
CA2853100A1 (en) * 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
JP6411214B2 (ja) 2011-11-11 2018-10-24 ユーシービー バイオファルマ エスピーアールエル アルブミン結合抗体及びその結合断片
CA2859665C (en) * 2011-12-20 2024-05-21 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
EP2885010B1 (en) * 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
JP6284548B2 (ja) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ヒト抗タウ抗体
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
SG10202010735PA (en) 2015-07-06 2020-11-27 UCB Biopharma SRL Tau-binding antibodies

Similar Documents

Publication Publication Date Title
JP2019122405A5 (enExample)
JP2022519118A5 (enExample)
JP2020039360A5 (enExample)
JP2016513682A5 (enExample)
JP2019522961A5 (enExample)
JP2016512551A5 (enExample)
JP2020514277A5 (enExample)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2017113028A5 (enExample)
JP2013198490A5 (enExample)
JP2020508655A5 (enExample)
JP2018516853A5 (enExample)
JP2020504101A5 (enExample)
JP2017052784A5 (enExample)
JP2017528476A5 (enExample)
RU2016125489A (ru) Нейтрализующие моноклональные человеческие антитела против интерлейкина-33
RU2017125758A (ru) Антитела к с5 и способы их применения
JP2012502649A5 (enExample)
JP2023551027A5 (enExample)
JP2016533763A5 (ja) ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物
JP2018510617A5 (enExample)
RU2013140350A (ru) Антитела против человеческого il33r и их применение
JP2020524661A5 (enExample)
JP2012531922A5 (ja) Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位
JP2016527225A5 (enExample)